KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)
Public ClinicalTrials.gov record NCT04165083. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Treatment Naïve Patients With PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC)
Study identification
- NCT ID
- NCT04165083
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 102 participants
Conditions and interventions
Conditions
Interventions
- MK-0482 Biological
- MK-4830 Biological
- Pembrolizumab Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 18, 2019
- Primary completion
- Oct 30, 2025
- Completion
- Oct 30, 2025
- Last update posted
- Nov 25, 2025
2019 – 2025
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center ( Site 0001) | Gilbert | Arizona | 85234 | — |
| City of Hope ( Site 0014) | Duarte | California | 91010 | — |
| UCSF Medical Center at Mission Bay ( Site 0007) | San Francisco | California | 94158 | — |
| Georgetown University ( Site 0036) | Washington D.C. | District of Columbia | 20007 | — |
| University of Kentucky Markey Cancer Center ( Site 0019) | Lexington | Kentucky | 40536-0293 | — |
| MedStar Franklin Square Medical Center ( Site 0033) | Baltimore | Maryland | 21237 | — |
| Massachusetts General Hospital ( Site 0003) | Boston | Massachusetts | 02114 | — |
| Dana Farber Cancer Institute ( Site 0002) | Boston | Massachusetts | 02215 | — |
| Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031) | Omaha | Nebraska | 68130 | — |
| Dartmouth Hitchcock Medical Center ( Site 0016) | Lebanon | New Hampshire | 03766 | — |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0037) | Hackensack | New Jersey | 07601 | — |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0034) | New York | New York | 10016 | — |
| Sanford Fargo Medical Center ( Site 0039) | Fargo | North Dakota | 58102 | — |
| Cleveland Clinic Main ( Site 0006) | Cleveland | Ohio | 44195 | — |
| Ohio State University Comprehensive Cancer Center ( Site 0015) | Columbus | Ohio | 43210 | — |
| Abramson Cancer Center of the University of Pennsylvania ( Site 0010) | Philadelphia | Pennsylvania | 19104 | — |
| Sanford Cancer Center ( Site 0038) | Sioux Falls | South Dakota | 57104 | — |
| The University of Texas MD Anderson Cancer Center ( Site 0009) | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04165083, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 25, 2025 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04165083 live on ClinicalTrials.gov.